Unjoni Ewropea - Malti - EMA (European Medicines Agency)

biogen idec ltd - daclizumab - sklerosi multipla - immunosoppressanti - zinbryta huwa indikat f'pazjenti adulti għat-trattament ta 'forom ta' sklerożi multipla li tirkadi (rms).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

biogen netherlands b.v. - nusinersen sodium - atrofija muskolari, spinali - drogi oħra tas-sistema nervuża - spinraza hija indikata għat-trattament ta '5q atrofija muskolari spinali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

mylan pharmaceuticals limited - anagrelide hydrochloride - tromboċitemja, essenzjali - aġenti antineoplastiċi - anagrelide huwa indikat għat-tnaqqis tal-għadd għoli tal-plejtlets f'mill-riskju tromboċitemja essenzjali (et) tal-pazjenti li jkunu intolleranti għall it-terapija attwali tagħhom jew li l-għadd għoli tal-plejtlets tagħhom ma jitnaqqasx għal-livell aċċettabbli bit-terapija attwali tagħhom. an at-risk patientan at-risk essential thrombocythaemia patient is defined by one or more of the following features:>60 years of age ora platelet count >1,000 x 10⁹/l ora history of thrombo-haemorrhagic events.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

alnylam netherlands b.v. - patisiran sodium - amilojdożi, familjali - drogi oħra tas-sistema nervuża - onpattro huwa indikat għall-kura ta ' transthyretin medjat amilojdożi (hattr amilojdożi) f'pazjenti adulti bil-istadju ta'l-1 jew l-istadju 2 polinewropatija.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

rad neurim pharmaceuticals eec sarl - melatonin - sleep initiation and maintenance disorders; autistic disorder - psikolettiċi - slenyto huwa indikat għat-trattament ta 'nuqqas ta' rqad fit-tfal u l-adolexxenti ta ' minn 2-18-il bl-awtiżmu-ispettru disturb (petite) u / jew smith-magenis-sindromu, fejn l-irqad-iġjene miżuri ġew insuffiċjenti.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

ultragenyx germany gmbh - vestronidase alfa - mucopolysaccharidosis vii - l-enżimi - mepsevii huwa indikat għall-kura ta 'manifestazzjonijiet mhux newroloġiċi ta' mucopolysaccharidosis vii (mps vii; hekk syndrome).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

alnylam netherlands b.v. - givosiran - porphyrias, tal-fwied - varji ta'l-apparat alimentari u tal-metaboliżmu-prodotti - it-trattament ta akuta tal-fwied, porfirja (huma maħsuba) fl-adulti u adolexxenti minn 12-il sena u anzjani.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

alnylam netherlands b.v. - lumasiran sodium - hyperoxaluria, primary - oħra tal-passaġġ alimentari u tal-metaboliżmu-prodotti, - treatment of primary hyperoxaluria type 1 (ph1) in all age groups.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pfizer europe ma eeig - somatrogon - growth and development - pitwitarja u l-assi ipotalamika-ormoni u analogi - indicated for the long-term treatment of paediatric patients with growth disturbance due to insufficient secretion of growth hormone.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

rad neurim pharmaceuticals eec sarl - melatonin - sleep inizjattiva u maintenance disorders - psikolettiċi - melatonin neurim is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.